Usio Inc (USIO) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.04. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -125%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced earnings of $0.02, delivering a surprise of 300%.Over the last four quarters, the company has surpassed consensus EPS es ...

Jack In The Box (JACK) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.19%. A quarter ago, it was expected that this burger chain would post earnings of $1.71 per share when it actually produced earnings of $1.92, delivering a surprise of 12.28%.Over the last four quarters, the comp ...

Core Viewpoint - Janus International Group, Inc. (JBI) has shown a significant price increase of 35.6% over the past four weeks, with a mean price target of $10.80 indicating a potential upside of 27.1% from the current price of $8.50 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $3.11, indicating variability among analysts; the lowest estimate is $7 (17.7% decline), while the highest is $14 (64.7% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, although it does not guarantee the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about JBI's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 35.4% over the past month, with no negative revisions reported [12] - JBI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]

Group 1 - Edgewise Therapeutics, Inc. (EWTX) shares have increased by 14.4% over the past four weeks, closing at $14.89, with a mean price target of $40.90 indicating a potential upside of 174.7% [1] - The average of 10 short-term price targets ranges from a low of $14 to a high of $52, with a standard deviation of $14.28, suggesting variability in analyst estimates [2] - Analysts show strong agreement on EWTX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for EWTX's current year earnings has increased by 6.8% over the past month, with four estimates rising and one falling [12] - EWTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for price movement [13]

Core Insights - ADC Therapeutics SA reported a quarterly loss of $0.36 per share, which is better than the Zacks Consensus Estimate of a loss of $0.38, and an improvement from a loss of $0.56 per share a year ago [1] - The company achieved revenues of $23.03 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 26.94% and up from $18.05 million year-over-year [2] - The stock has underperformed, losing approximately 33.7% since the beginning of the year, while the S&P 500 has gained 0.1% [3] Financial Performance - Over the last four quarters, ADC Therapeutics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $18.73 million, and for the current fiscal year, it is -$1.65 on revenues of $75.43 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ADC Therapeutics belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, particularly following management's commentary on the earnings call [3][4] - The current Zacks Rank for ADC Therapeutics is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -32.26%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.18, delivering a surprise of 5.26%.Over the last four quarters, the company has surp ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50.70%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the compan ...

Kamada (KMDA) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical would post earnings of $0.05 per share when it actually produced earnings of $0.07, delivering a surprise of 40%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Kamada, which belongs to the Zack ...

European Wax Center, Inc. (EWCZ) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 340%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.16, delivering a surprise of 220%.Over the last four quarters, the co ...

Actelis Networks, Inc. (ASNS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced a loss of $0.26, delivering a surprise of -1,200%.Over the last four quarters, the company has sur ...